Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members Business Wire - Wed Jun 3, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced...

TEM : 52.26 (+10.00%)
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH Business Wire - Mon Jun 1, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH , a next-generation...

TEM : 52.26 (+10.00%)
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development Business Wire - Sun May 31, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform...

TEM : 52.26 (+10.00%)
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community Business Wire - Sat May 30, 7:30AM CDT

Inaugural program provides unprecedented access to Tempus’ library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical breakthroughs...

TEM : 52.26 (+10.00%)
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results Business Wire - Sat May 30, 7:00AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically...

TEM : 52.26 (+10.00%)
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology Business Wire - Fri May 29, 8:15AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at...

TEM : 52.26 (+10.00%)
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio Business Wire - Fri May 29, 7:15AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a...

TEM : 52.26 (+10.00%)
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology Business Wire - Thu May 28, 7:30AM CDT

Expanded platform delivers patient insights across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers

TEM : 52.26 (+10.00%)
Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows Business Wire - Wed May 27, 7:33AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub , its AI-enabled...

TEM : 52.26 (+10.00%)
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting Business Wire - Tue May 26, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American...

TEM : 52.26 (+10.00%)

Barchart Exclusives

UnitedHealth Just Raised Its Dividend 5%. Why You Should Buy UNH Stock Here. Barchart - 37 minutes ago
UnitedHealth Group raised its quarterly dividend by 5% to $2.32 per share, marking its 16th consecutive year of dividend increases amid a challenging health insurance environment with rising medical costs. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.